SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is experiencing significant buzz following MSCI's decision not to exclude digital asset treasury companies from its indexes, dispelling a major bearish concern. This news is fueling anticipation of a substantial rally and short squeezes among bulls who believe the stock was undervalued, though some skeptics remain focused on potential dilution and Bitcoin's volatile price action.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is a major talking point as geopolitical focus intensifies on Greenland's strategic rare earth deposits, highlighted by U.S. administration comments. The community widely discusses the potential for government investment or partnership, viewing CRML's Tanbreez project as vital for Western supply chain independence from key mineral producing nations and speculating on substantial gains.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as the community eagerly anticipates the completion of its Northern Data acquisition, poised to significantly expand its AI and cloud capabilities. This move, coupled with substantial investment and service commitments from Tether, fuels widespread discussion about a potential short squeeze due to high short interest, alongside excitement for the imminent Rumble Wallet launch and the return of key content creators.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending after experiencing a sharp price drop, which many in the community attribute to competitive downgrades from Bank of America and Goldman Sachs following a recent equity offering. Investors are actively debating whether this is market manipulation by legacy institutions to acquire shares at a lower price, especially ahead of highly anticipated earnings and potential S&P 500 inclusion. Despite the decline, many view the dip as a strategic buying opportunity, confident in SoFi's long-term prospects as a fintech disruptor.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as market participants digest a major competitor's oral GLP-1 launch and its potential impact on pricing and competition. Community sentiment is sharply divided, with advocates highlighting VK2735's strong clinical profile and anticipating upcoming catalysts like the J.P. Morgan conference and FDA feedback on its oral program, while critics point to management's "go it alone" stance and recent insider share sales as causes for concern. This intense debate plays out against the backdrop of an expanding yet highly competitive obesity treatment landscape.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing immense investor interest, driven by the surging demand for memory and storage within the AI supercycle and reports of deepening industry shortages. The community is sharply divided, with bulls pointing to its market-leading momentum and short squeeze potential, while skeptics question the sustainability of its rapid ascent. This intense discussion reflects broader sector strength in AI infrastructure.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus (MNTS) is experiencing a surge following news of its innovative 3D-printed fuel tank, slated for flight testing on an upcoming SpaceX mission, igniting strong community interest in the aerospace sector. Investors are actively discussing its low float and high short interest, with many anticipating significant growth and comparing it to a "mini SpaceX" within the expanding space and defense industry.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is trending due to its recently executed agreement with the U.S. Department of Energy (DOE) for Project TETRA, a pilot reactor initiative to advance its Integral Molten Salt Reactor technology. The community views this as a significant validation, sparking comparisons to OKLO and intense discussion about IMSR's potential as a long-term player in meeting future energy demands, especially for AI infrastructure, amidst debates on its valuation and recent market performance.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending significantly following reports that Eli Lilly is nearing a deal to acquire the company for over $1 billion. This potential buyout has ignited widespread community discussion about the strategic value of Ventyx's oral inflammatory-disease drugs, especially its NLRP3 inhibitors, and their synergistic potential with major pharmaceutical pipelines. Many are actively speculating on the final acquisition price and the potential for a substantial short squeeze.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis Inc. is trending sharply after announcing overwhelmingly positive Phase 3 clinical trial results for its psoriasis drug, envudeucitinib, showcasing high efficacy and a favorable safety profile. The community is largely bullish, highlighting significant upside potential and revised analyst price targets due to the drug's 'best in class' data. However, there's also active discussion and speculation among traders regarding a proposed public offering and its potential short-term impact on the stock's trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Mangoceuticals believes the current crypto market offers a strategic opportunity to capitalize on current price levels.</li><li>The company has appointed Cube Group as the asset manager for its DAT.</li><li>As part of the MULTI-DAT framework, the company is pursuing a range of strategic digital asset and DeFi initiatives to enhance its treasury operations further.</li></ul>Health and wellness company Mangoceuticals <a href="https://stocktwits.com/symbol/MGRX">(MGRX</a>) on Friday announced that it is launching a Solana-focused digital asset treasury (DAT) of up to $100 million through its newly formed subsidiary, Mango DAT, in partnership with Cube Group.Cube Group has been appointed as the asset manager responsible for custody and execution.<h2 class="st-heading-2">Strategic Opportunity</h2>Mangoceuticals believes that the current crypto market offers a strategic opportunity to capitalize on current prices, enabling optimized entry points for long-term value creation. "We are optimistic about Solana’s future and confident this strategy will provide compelling, non-dilutive returns while positioning Mangoceuticals as a leader at the intersection of traditional finance and blockchain technology," said Jacob Cohen, Founder and CEO of Mangoceuticals.Solana’s&nbsp;<a href="https://stocktwits.com/coins/solana">price</a> was trading 1.7% higher at around $125.47 at the time of writing. Meanwhile, Mangoceuticals shares slumped nearly 47% on Friday. Retail sentiment around Mangoceuticals on Stocktwits trended in “extremely bullish” amid “extremely high” message volume.&nbsp;<figure class="image"><img style="aspect-ratio:633/73;" src="https://news.stocktwits-cdn.com/MGRX_PNG_9360d011fb.webp" alt="Retail sentiment around Mangoceuticals on Stocktwits trended in “extremely bullish” amid “extremely high” message volume. " width="633" height="73"></figure><h2 class="st-heading-2">MULTI-DAT Framework</h2>Mangoceuticals has recently filed a trademark&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://tsdr.uspto.gov/#caseNumber=99483190&amp;caseSearchType=US_APPLICATION&amp;caseType=DEFAULT&amp;searchType=statusSearch">application</a> for MULTI-DAT to the United States Patent and Trademark Office, signaling its strategic expansion into the digital asset sector.As part of the MULTI-DAT framework, the company is pursuing a range of strategic digital asset and DeFi initiatives to enhance its treasury operations further. This will allow the firm to conduct various financial operations, including facilitating virtual currency transactions and exchanges, processing electronic fund transfers, managing investment portfolios, and running blockchain-driven cryptocurrency services.&nbsp;By diversifying its activities, Mangoceuticals aims to mitigate the risks associated with market volatility, which often affects strategies that depend solely on token price movements.A Digital Asset Treasury is a type of firm that buys and holds cryptocurrencies on its balance sheet. One of the biggest DAT companies is Michael Saylor-backed Strategy (MSTR), which began buying bitcoin in 2020 and has been continuing to do so ever since. Notably, the number of DAT companies has expanded over the years.According to&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.dlapiper.com/en/insights/publications/2025/10/key-capital-market-trends-digital-asset-treasuries">DLA Piper</a>, as of September 2025, more than 200 companies had adopted DAT strategies, with more than 190 focused on BTC treasuries and another 10-20 on alternative digital assets.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Solana logo displayed on a phone screen and representation of cryptocurrencies are seen in this illustration photo taken in Krakow, Poland on August 21, 2021. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Mangoceuticals Announces Solana-Focused $100M Digital Asset Treasury, Sees ‘Compelling, Non-Dilutive Returns’

Mangoceuticals had also recently filed a trademark application for “MULTI-DAT” with the United States Patent and Trademark Office in a bid to expand into the digital asset space

Cryptocurrency

Mangoceuticals had also recently filed a trademark application for “MULTI-DAT” with the United States Patent and Trademark Office in a bid to expand into the digital asset space. 

Insider Selling: Mangoceuticals (NASDAQ:MGRX) CFO Sells 10,000 Shares of Stock

Mangoceuticals, Inc. (NASDAQ:MGRX - Get Free Report) CFO Eugene Johnston sold 10,000 shares of Mangoceuticals stock in a transaction that occurred on Friday, December 5th. The shares were sold at an...

Insider Selling: Mangoceuticals (NASDAQ:MGRX) Director Sells 125,000 Shares of Stock

Mangoceuticals, Inc. (NASDAQ:MGRX - Get Free Report) Director Alex Hamilton sold 125,000 shares of the stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of...

<ul class="summary-bullets"><li>The obesity medications will be made available to both MangoRx and PeachesRx customers through Eli Lilly’s LillyDirect Self-Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy, Mangoceuticals said.</li><li>The drugs will be available for home delivery for as low as $499 per month, the company added.</li><li>A Novo Nordisk spokesperson noted in an emailed statement that the company “was not made aware of the announcement.”</li></ul>Shares of Mangoceuticals, Inc. (MGRX) jumped 23% in the pre-market session on Thursday after the telehealth company announced the launch of programs that provide direct access to authentic weight loss medicines from drugmakers Eli Lilly and Novo Nordisk.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5668113967057105&amp;symbol=MGRX">said</a> that it has launched two programs called MangoRx Direct and PeachesRx Direct to provide direct access to Lilly’s Zepbound and Novo’s Wegovy medicines.<h2 class="st-heading-2">How Will The Partnership Work?</h2>Customers can receive virtual consultations with providers on Mangoceuticals’ telehealth platform and get personalized obesity and weight management plans and also get their GLP-1 medicines delivered to them.The obesity medications will be made available to both MangoRx and PeachesRx customers through Eli Lilly’s LillyDirect Self-Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy. Both NovoCare and LillyDirect are aimed at providing medicines direct-to-consumer. While LillyDirect was launched last year, NovoCare was started earlier this year.The drugs will be available for home delivery for as low as $499 per month, the company said. Customers can also opt to pick up their prescriptions at a neighborhood pharmacy of their choice.“No insurance is required, making the programs ideal for self-pay, uninsured, underinsured and high-deductible patients,” Mangoceuticals CEO Jacob Cohen said.<h2 class="st-heading-2">Novo Nordisk’s Statement</h2>A Novo Nordisk spokesperson noted in an emailed statement that the company “was not made aware of the announcement issued this morning by Mangoceuticals. We do not have any agreement or partnership with this company.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MGRX">MGRX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.MGRX stock is down by 27% this year and by 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/mrsn-stock-soars-pre-market-after-day-one-acquisition-deal/cLP9RQdRE3Q">MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]comEditor's Note: The story has been updated with Novo Nordisk's emailed statement.

Rising stock market chart on a trading board background.

Why Did Mangoceuticals Shares Rise Today?

 The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines.

Equity

 The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines.


Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company was founded on October 7, 2021 and is headquartered in Dallas, TX.

Mangoceuticals Inc

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$0.869
Prev Close	$0.829
Open	$0.8395
Dividend Yield	0.00%
50-Day Moving Average	$1.31
Beta	0.00
Avg. Volume	1.05M
PE Ratio	-0.30

52-Week High	$6.15
52-Week Low	$0.5241
Market Capitalization	$12.76M
EPS (Annual)	-$4.40
Price to Book	0.77
Revenue Per Employee	$205,291.00
Enterprise Value/EBITDA	N/A

MGRX
Mangoceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MGRX News

MGRXMangoceuticals Inc